CRYPTOLOGY-ASSET-GROUP
3.6.2021 09:59:05 CEST | Business Wire | Press release
Cryptology Asset Group (ISIN: MT0001770107; Ticker: CAP:GR), a leading European investment company for blockchain- and crypto-related businesses founded by Christian Angermayer and Mike Novogratz, intends to invest USD 100 million over the next 24 months into crypto-related venture funds.
Cryptology will take an entrepreneurial approach in building its fund portfolio and will focus on first time funds and emerging managers, globally, including seeding funds and taking stakes in GPs as well.
Christian Angermayer, Founder of Cryptology, explains: "We are at the very beginning of the crypto revolution, and we strive to become one of the leading global investors in this very nascent asset class. Our fund investment strategy will focus on emerging talent, taking a global approach, and will encompass both funds investing in equity stakes of crypto- and blockchain related companies as well as funds investing in crypto assets and tokens."
Patrick Lowry, CEO of Cryptology, adds: "There is no better asset class to bet on than crypto, in my opinion. Within just three years, Cryptology has grown invested capital of approx. EUR 27 million into an NAV of approx. EUR 450 million, as of June 1, 2021. This results in an estimated IRR of more than 300% per year, which is an impressive testimony to the tectonic shift we are seeing in front of our very eyes. We will work hard to continue this success story in the coming years and decades.
Patrick further elaborates: "With regards to our fund investment strategy, our vision is to collaborate closely with our portfolio funds, offering them access to our broad network and experience, as well as to co-invest alongside them into innovative blockchain companies and crypto assets."
Cryptology is one of the few stock-market listed investment companies exclusively focusing on crypto and blockchain related businesses, trading on multiple German exchanges under the ticker symbol CAP:GR and ISIN MT0001770107.
Cryptology offers retail and institutional investors unparalleled and easy access, via its daily liquid shares, to an exclusive asset class that is otherwise reserved for a small group of investors, given that most companies and funds in the crypto sector are still private. For example, Cryptology offers indirect participation in iconic crypto giant Block.one, the publishers of EOSIO, and their newly announced exchange, BULLISH.
Cryptology's fund investment strategy will strengthen its position as the leading access stock to a global, diversified crypto portfolio.
About Cryptology Asset Group p.l.c.
Cryptology is a leading European investment company for crypto assets and blockchain-related business models. Founded by Christian Angermayer's family office, Apeiron Investment Group and crypto-legend Mike Novogratz, Cryptology is the largest publicly traded holding company for blockchain- and crypto-based business models in Europe. Noteworthy portfolio companies include crypto-giant and EOSIO software publisher Block.one, leading HPC provider Northern Data, commission-free online neobroker nextmarkets, and crypto asset management group Iconic Funds.
| Language: | English | |
| Company: | Cryptology Asset Group PLC | |
| Beatrice 66 & 67, Amery Street | ||
| SLM 1707 Sliema | ||
| Malta | ||
| E-mail: | info@cryptology-ag.com | |
| Internet: | cryptology-ag.com | |
| ISIN: | MT0001770107 | |
| WKN: | A2JDEW | |
| Listed: | Regulated Unofficial Market in Dusseldorf | |
| EQS News ID: | 1203868 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005409/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom